The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Ikaros and leukaemia

(2015) Linda Olsson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Motor, linguistic, personal and social aspects of children with Down syndrome

(2015) Amanda Tragueta FERREIRA-VASQUES et al.   Journal of Applied Oral Science

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3

(2015) Benjamin J. Thompson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Novel immunotherapies in lymphoid malignancies

(2015) Connie Lee Batlevi et al.   Nature Reviews Clinical Oncology

Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan

(2015) Takashi Taga et al.   PEDIATRIC BLOOD & CANCER

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

(2015) Ramzi Abbassi et al.   PHARMACOLOGY & THERAPEUTICS

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

(2015) Kathryn G. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms

(2014) Raajit Rampal et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The molecular regulation of Janus kinase (JAK) activation

(2014) Jeffrey J. Babon et al.   BIOCHEMICAL JOURNAL

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

(2014) Katharine Patrick et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation

(2014) Ulf Soppa et al.   CELL CYCLE

Refractive error, binocular vision and accommodation of children with Down syndrome

(2014) Tanisha Watt et al.   Clinical and Experimental Optometry

Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries

(2014) Catarina Lundin et al.   Journal of Hematology & Oncology

Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia

(2014) Yilong Li et al.   NATURE

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation

(2014) Andrew A Lane et al.   NATURE GENETICS

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome

(2014) Johann K. Hitzler et al.   PEDIATRIC BLOOD & CANCER

Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome

(2014) Hiroaki Goto et al.   PEDIATRIC BLOOD & CANCER

DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson’s disease

(2014) M J Barallobre et al.   Cell Death & Disease

Prognosis and management of acute myeloid leukemia in patients with Down syndrome

(2014) J Timothy Caldwell et al.   Expert Review of Hematology

The genomic landscape of acute lymphoblastic leukemia in children and young adults

(2014) C. G. Mullighan   Hematology-American Society of Hematology Education Program

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

(2013) T. D. Buitenkamp et al.   BLOOD

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle

(2013) Jia-Yun Chen et al.   MOLECULAR CELL

IKZF1deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan

(2013) Daisuke Asai et al.   Cancer Medicine

Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel

(2012) U. Creutzig et al.   BLOOD

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

(2012) S. K. Tasian et al.   BLOOD

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2012) S. L. Maude et al.   BLOOD

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome

(2012) Sébastien Malinge et al.   JOURNAL OF CLINICAL INVESTIGATION

Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia

(2012) C Bohnstedt et al.   LEUKEMIA

Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations

(2012) T D Buitenkamp et al.   LEUKEMIA

Acute leukemias in children with Down syndrome

(2012) Laura Seewald et al.   MOLECULAR GENETICS AND METABOLISM

Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21

(2012) A. Roy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia

(2011) V. Rand et al.   BLOOD

Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling

(2011) B. Hammerle et al.   DEVELOPMENT

DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly

(2011) L. Litovchick et al.   GENES & DEVELOPMENT

Gain-of-function mutations ininterleukin-7 receptor-α(IL7R) in childhood acute lymphoblastic leukemias

(2011) Chen Shochat et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles

(2011) M G Loudin et al.   LEUKEMIA

Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A

(2011) Shaohong Ding et al.   NEUROBIOLOGY OF AGING

Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group

(2010) K. W. Maloney et al.   BLOOD

Similar yet different

(2010) S. Izraeli   BLOOD

CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis

(2010) J. D. Roll et al.   CANCER RESEARCH

Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia

(2010) T. D. Buitenkamp et al.   HAEMATOLOGICA

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

(2009) L. Hertzberg et al.   BLOOD

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

(2009) L. J. Russell et al.   BLOOD

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

(2009) Kwan-Hyuck Baek et al.   NATURE

Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

(2009) Charles G Mullighan et al.   NATURE GENETICS

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

(2009) A. Yoda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

(2008) L. Kearney et al.   BLOOD

Prevalence and clinical correlates ofJAK2mutations in Down syndrome acute lymphoblastic leukaemia

(2008) Amos Gaikwad et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acute lymphoblastic leukemia and Down syndrome

(2008) Maurizio Arico et al.   CANCER

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET

Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome

(2007) G. Kirsammer et al.   BLOOD